ProAssurance Announces Merger with The Doctors Company
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ProAssurance ( (PRA) ) has issued an update.
On March 19, 2025, ProAssurance announced a merger agreement with The Doctors Company, where ProAssurance will become a wholly owned subsidiary. The merger includes provisions for executive compensation adjustments to mitigate tax impacts, reflecting the company’s strategic alignment with its performance targets for 2025.
The most recent analyst rating on (PRA) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on ProAssurance stock, see the PRA Stock Forecast page.
Spark’s Take on PRA Stock
According to Spark, TipRanks’ AI Analyst, PRA is a Neutral.
ProAssurance’s overall score is primarily influenced by its financial performance, which shows significant challenges in revenue growth and cash flow management. The technical analysis suggests a neutral market sentiment, while the valuation indicates the stock is relatively expensive. The strong balance sheet provides some stability, but improvements in cash flow and operational efficiency are crucial for future growth.
To see Spark’s full report on PRA stock, click here.
More about ProAssurance
ProAssurance is involved in the insurance industry, focusing on providing medical professional liability insurance and other related products. The company has a market focus on healthcare providers and institutions, offering risk management and insurance solutions.
Average Trading Volume: 369,797
Technical Sentiment Signal: Buy
Current Market Cap: $1.23B
For a thorough assessment of PRA stock, go to TipRanks’ Stock Analysis page.
